MIOSTAT .1 mg/mL (Carbachol SOLUTION) .1 mg/mL

Carbachol, the active ingredient in MIOSTAT, activates muscarinic receptors in the eye. This action causes contraction of the sphincter pupillae muscle, leading to miosis (constriction of the pupil). It also increases the outflow of aqueous humor, which helps reduce intraocular pressure.

The dosage of MIOSTAT is determined by a healthcare professional based on the specific condition being treated. It is typically administered as an intraocular injection during surgery. The exact dose and administration method should be followed as prescribed.

The safety of MIOSTAT during pregnancy or breastfeeding has not been established. It is important to consult with a healthcare provider before using MIOSTAT if you are pregnant, planning to become pregnant, or breastfeeding.

To order MIOSTAT from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. The team will ask you to confirm your trade or institutional credentials and will reply with pricing, availability, shipping, and the necessary import paperwork.

MIOSTAT is a specific formulation of carbachol designed for intraocular use. It is particularly effective in inducing miosis during surgery and managing intraocular pressure. Compared to other miotic agents, MIOSTAT's unique formulation and strength make it suitable for specific ophthalmic procedures.

MIOSTAT should be stored at 15° - 30°C (59° - 86°F). Keep it in the original packaging, protect from moisture and light, and ensure the container is undamaged. Follow the storage instructions provided with the product to maintain its effectiveness.

MIOSTAT is administered as an intraocular injection during surgery. A healthcare professional will aseptically remove the sterile vial, withdraw the contents into a sterile syringe, and instill it into the anterior chamber of the eye. The exact administration method should be followed as prescribed.

The most serious risks associated with MIOSTAT include increased intraocular pressure, inflammation of the eye, corneal edema, persistent bullous keratopathy, and retinal detachment or postoperative iritis following cataract extraction. Patients should be monitored for these adverse effects.

MIOSTAT should not be used by patients with acute cardiac failure, bronchial asthma, peptic ulcers, hyperthyroidism, G.I. spasm, urinary tract obstruction, or Parkinson's disease. Additionally, patients with a known allergy to carbachol or any of the inactive ingredients in MIOSTAT should avoid using it.